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Background: The efficacy of thrombolytic therapy for acute ischemic stroke remains controversial in
emergency medicine and has not been fully endorsed by either the American College of Emergency
Physicians or the American Academy of emergency medicine. A growing recognition exists of the
influence of pharmaceutical sponsorship on the reported findings of published clinical trials.
Sponsorship bias has been suggested as a potential criticism of the literature and guidelines favoring
thrombolytic therapy.
Objective: The objective of this study is to review the most influential literature regarding thrombolytic
therapy for acute ischemic stroke and document the presence or absence of pharmaceutical
sponsorship.
Methods: A publication-citation analysis was performed to identify the most frequently cited articles
pertaining to thrombolytic therapy for acute ischemic stroke. Identified articles were reviewed for
disclosures of pharmaceutical funding.
Results: Of the 20 most-cited articles pertaining to thrombolytic therapy for acute stroke, 17 (85%)
disclosed pharmaceutical sponsorship. These disclosures range from general sponsorship to direct
employment of authors by pharmaceutical companies.
Conclusion: An overwhelming predominance of the most influential literature regarding thrombolytic
therapy for acute ischemic stroke is susceptible to sponsorship bias. This potential bias may provide a
basis for physician concern regarding the efficacy and safety of thrombolytic therapy. Further, large,
independent, placebo-controlled studies may be required to guide therapy and professional guidelines
definitively for acute ischemic stroke. [West J Emerg Med. 2011;12(4):435–441.]
INTRODUCTION
Stroke is one of the leading causes of death and
disability in developed countries.
1 Recombinant tissue
plasminogen activator (rTPA) is an approved thrombolytic
therapy for use in acute ischemic stroke, approved by the
Food and Drug Administration in 1996 and endorsed in
guidelines from the American Heart Association (AHA).
2,3
However, 15 years after the original National Institute of
Neurologic Disorders Study (NINDS) of rTPA for acute
stroke, only 2% to 3% of eligible patients receive
thrombolytic treatment.
4
A 2006 survey of members of the American College of
Emergency Physicians (ACEP) found that 40% of physicians
would not use thrombolytic therapy for acute stroke, even
under ideal conditions.
5 The professional societies ACEP and
the Academy of Academic Emergency Medicine (AAEM)
decline to endorse thrombolytic therapy fully as the standard
of care.
6,7 One source of reticence to the use of thrombolytic
therapy stems from concern over the role of pharmaceutical
ﬁnancial interests in establishing treatment guidelines.
8,9
Critics cite Genentech contributions to the AHA totaling $11
million in the years preceding the issuance of stroke
guidelines; a majority of panelists voting on the guidelines
had ties to Genentech. More recently, the AHA has again
Volume XII, NO. 4 : November 2011 Western Journal of Emergency Medicine 435Table 1. Most-cited articles in thrombolytic therapy and pharmaceutical disclosures.
Title Journal Year Citations
Stated
disclosures*
Types of
disclosures
Tissue plasminogen activator for
acute ischemic stroke. The
National Institute of
Neurological Disorders and
Stroke rt-PA Stroke Study
Group
32
NEJM 1995 3,592 Genentech Provided study drug;
performed study monitoring
Intravenous thrombolysis with
recombinant tissue
plasminogen activator for
acute hemispheric stroke. The
European Cooperative Acute
Stroke Study (ECASS)
33
JAMA 1995 1,478 Boehringer Ingelheim Study sponsor; ‘‘continuous
support and high-quality
professional input’’
Intra-arterial prourokinase for
acute ischemic stroke. The
PROACT II study: a
randomized controlled trial
Prolyse in Acute Cerebral
Thromboembolism
34
JAMA 1999 1,164 Abbott Laboratories Study sponsor; authors
served as paid consultants
and received honoraria
Randomised double-blind
placebo-controlled trial of
thrombolytic therapy with
intravenous alteplase in acute
ischaemic stroke (ECASS II
Second European-
Australasian Acute Stroke
Study Investigators)
35
Lancet 1998 972 Boehringer Ingelheim Study sponsor; sponsor
randomized patients,
performed study monitoring
and data management
Association of outcome with
early stroke treatment: pooled
analysis of ATLANTIS,
ECASS, and NINDS rt-PA
stroke trials
36
Lancet 2004 760 Boehringer Ingelheim,
Genentech
Authors receive funding;
author has research supply
agreement; author is
employee of Boehringer
Ingelheim
Recombinant tissue-type
plasminogen activator
(Alteplase) for ischemic stroke
3 to 5 hours after symptom
onset. The ATLANTIS study:
a randomized controlled trial.
Alteplase Thrombolysis for
Acute Noninterventional
Therapy in Ischemic Stroke
37
JAMA 1999 478 Genentech Study sponsor; sponsor
conducted data
management and analysis
Recombinant tissue
plasminogen activator in
acute thrombotic and embolic
stroke
38
Annals of Neurology 1992 468 None Burroughs-Wellcome
Company sponsored
Thrombolysis with alteplase 3 to
4.5 hours after acute ischemic
stroke
39
NEJM 2008 429 Boehringer Ingelheim Study sponsor; authors
served as paid consultants,
received honoraria, and
received grant funding;
authors are employees of
Boehringer Ingelheim
The Desmoteplase in Acute
Ischemic Stroke Trial (DIAS):
a phase II MRI-based 9-hour
window acute stroke
thrombolysis trial with
intravenous desmoteplase
40
Stroke 2005 404 PAION Study sponsor
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Title Journal Year Citations
Stated
disclosures*
Types of
disclosures
Randomised controlled trial of
streptokinase, aspirin, and
combination of both in
treatment of acute ischemic
stroke. Multicentre Acute
Stroke Trial–Italy (MAST-I)
Group
41
Lancet 1995 343 Pharmacia
Thereapeutics,
Pierrel SpA, Sanofi-
Winthrop
Study sponsor
Use of tissue-type plasminogen
activator for acute ischemic
stroke: the Cleveland area
experience
42
JAMA 2000 337 Genentech, Abbott
Laboratories
Authors served as paid
consultants and received
honoraria
Intravenous tissue-type
plasminogen activator for
treatment of acute stroke: the
Standard Treatment with
Alteplase to Reverse Stroke
(STARS) study
43
JAMA 2000 319 Genentech Study sponsor; authors serve
as paid speakers; author is
employee of Genentech
Ultrasound-enhanced systemic
thrombolysis for acute
ischemic stroke
44
NEJM 2004 314 Alsius, Boehringer
Ingelheim, Bristol-
Myers Squibb,
Encysive
Pharmaceuticals,
Genentech, Novo
Nordisk, Ono
Pharmaceuticals,
Sanofi-Synthelabo
Study sponsor; authors
served as paid consultants,
received honoraria, and
received grant funding;
authors hold patent on
medical device
Early stroke treatment
associated with better
outcome: the NINDS rt-PA
stroke study
45
Neurology 2000 310 Genentech Provided study drug;
performed study monitoring
Urgent therapy for stroke. Part I.
Pilot-study of tissue
plasminogen activator
administered within 90
minutes
46
Stroke 1992 307 None Genentech provided study
drug
Thrombolysis with alteplase for
acute ischaemic stroke in the
Safe Implementation of
Thrombolysis in Stroke-
Monitoring Study (SITS-
MOST): an observational
study
47
Lancet 2007 302 AGFA, AstraZeneca,
Aventis Behringer,
Boehringer
Ingelheim, Forest
Laboratories,
GlaxoSmithKline, H
Lundbeck, Novo
Nordisk, PAION,
Pfizer, Sanofi-
Aventis
Study sponsor; authors
served as paid consultants,
received honoraria, and
received grant funding
Thrombolytic therapy with
streptokinase in acute
ischemic stroke. The
Multicenter Acute Stroke
Trial–Europe Study Group
48
NEJM 1996 292 None AB Kabi provided study drug
Intravenous recombinant tissue
plasminogen-activator in
acute carotid artery territory
stroke
49
Neurology 1992 290 Sumitomo Study sponsor
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Clinical Practice Guidelines, raising ‘‘disturbing questions
about the independence and reliability’’ of the guidelines.
10,11
The inﬂuence of ﬁnancial ties is well documented in the
medical literature, with meta-analyses and systematic
reviews showing strong associations between pharmaceutical
funding and favorable published outcomes.
12,13
The goal of this study was to describe the role, if any, of
pharmaceutical ﬁnancial interests in the medical literature
regarding the use of thrombolytic therapy in acute stroke.
Citation analysis is an accepted, if controversial, method for
evaluating the impact of journals and faculty.
14,15 Although not
speciﬁcally described in the literature as applied to individual
articles, the same principles were extended in an attempt to
identify the most inﬂuential literature regarding the use of
thrombolytic therapy in acute ischemic stroke. The ISI Web of
Sciencet citation index was chosen because of ease of use and
completeness relative to competing sources.
16 Each article was
reviewed for ﬁnancial interests associated with the publication,
and the results used to discuss the potential conﬂict of interest
this may represent.
METHODS
An Internet search for articles concerning the use of
thrombolytic therapy for acute stroke was undertaken in
February 2011 at the ISI Web of Science web site. ‘‘All years’’
of the Science Citation Index-Expanded database from 1945 to
the present was searched by using the following search string:
‘‘Title¼(stroke AND (thrombolysis OR thrombolytic OR TPA
OR rTPA OR rt-PA OR tissue-plasminogen OR plasminogen
OR alteplase OR desmoteplase OR prourokinase OR
streptokinase)) AND Document Type¼(Article OR
Proceedings Paper).’’ The resulting search results were sorted
in descending order by the number of citations. After a
qualitative reading, articles that did not report on efﬁcacy of
thrombolysis as an intervention for acute stroke were excluded.
Twenty articles with the highest citation counts from this
remaining set were included for analysis.
Each article was reviewed for mention of pharmaceutical
ﬁnancial disclosures. A pharmaceutical ﬁnancial interest was
judged to be present if the text of the publication reported:
  Direct or indirect funding of a study by the pharma-
ceutical company manufacturing the study drug.
  The pharmaceutical company manufacturing the study
drug was involved in subject recruitment and site
monitoring.
  Any study authors or members of the study group
reported as a conflict of interest disclosure of receiving
employment by, professional association with, or receipt
of honoraria or grant funding from the pharmaceutical
company manufacturing the study drug.
Provision of the study drug without mention of other
study involvement was judged not to represent signiﬁcant
disclosure.
RESULTS
Initial search for the query string on the ISI Web of Science
showed 2,513 results. These results were ordered by number of
citations. One of the initial top 20 results concerned risk of
stroke and circulating endogenous tissue plasminogen activator
and was excluded.
17 A second article present in the top 20
results concerned neuroradiologic features of ischemic stroke
and was excluded.
18 The subsequent top 20 search results
constituted the main results and are listed in Table 1.
Pharmaceutical ﬁnancial disclosures are noted in 17 (85%)
of 20 articles reviewed. The companies named in disclosures for
each publication are listed in the table. If multiple companies are
listed in disclosures, they are listed in alphabetic order. A guide
to manufacturers of tissue plasminogen activator study drugs
Table 1. Continued.
Title Journal Year Citations
Stated
disclosures*
Types of
disclosures
Combined intravenous and
intra-arterial r-TPA versus
intra-arterial therapy of acute
ischemic stroke: Emergency
Management of Stroke (EMS)
Bridging Trial
50
Stroke 1999 269 Genentech Study sponsor
Streptokinase for acute
ischemic stroke with
relationship to time of
administration: Australian
Streptokinase (ASK) Trial
Study Group
51
JAMA 1996 248 Hoechst, IOOF
Australia
Study sponsor
* Companies listed in bold are manufacturers of tissue plasminogen activator. NEJM, New England Journal of Medicine; JAMA, Journal of
the American Medical Association.
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reporting disclosures had at least 1 disclosure involving the
pharmaceutical company manufacturing the study drug.
The type of disclosure identiﬁed in each article is shown in
Table 1. Of the articles with no disclosures, 1 was funded by the
Burroughs-Wellcome Company, an independent scientiﬁc
sponsor without industry associations.
19 The other 2 articles
judged to have no signiﬁcant disclosures each receiveda supply
of study medication. The ﬁrst speciﬁcally states the supplier
did not participate in data monitoring or data analysis. The last
makes no disclosures related to sponsorship. However,
although not providing a speciﬁc statement clarifying a lack of
conﬂict of interest, no further information is available, and it
will be assumed for the purposes of this article that none exists.
LIMITATIONS
This study has several limitations. Citation count in the
Web of Science is used as a surrogate marker for inﬂuence over
physician perception and decision making. It has been used to
deﬁne journal impact factor and as a tool in evaluating faculty
performance; however, citation count is not described as a
method to similarly quantify the inﬂuence of individual
articles.
Citation analysis by this method skews results by
publication age, as publications that have been available longer
are more likely to have increased numbers of citations. This is
most apparent when observing that only 5 of the 20 articles
reviewed were published in the last decade, whereas the
remaining 15 are more than 10 years old. Whereas articles
published longer in the past may form the foundation for
current research and standard of care, their actual inﬂuence over
physician perception and decision making may be limited, as
they, theoretically, reﬂect fewer contemporary data and less
practice.
The documentation of pharmaceutical ﬁnancial
disclosures is limited to that speciﬁcally stated in publication.
Omissions, unintentional or not, from the publication text may
underrepresent the degree to which pharmaceutical interests
inﬂuence the study.
Only 20 articles were reviewed for this analysis, rendering
the results more qualitative than quantitative.
DISCUSSION
Aworrying level of pharmaceutical ﬁnancial disclosure is
associated with the literature regarding thrombolysis in acute
stroke. Although pharmaceutical sponsorship is critical to the
approval of new medical therapies and the advancement of
medical sciences, this inﬂuence raises an unavoidable specter
of sponsorship bias. Sponsorship bias has been associated with
restriction of publication of negative results, alteration of the
primary outcomes after study completion, decreased adverse
event reporting, and discordance between author conclusions
and statistical results.
20–23 A meta-analysis revealed that
industry funding is signiﬁcantly associated with greater
chances of pro-industry results, with an odds ratio of 3.60 (95%
conﬁdence interval, 2.63–4.91). The degree to which
sponsorship bias is present in the reviewed studies represents
the extent to which this literature may mislead clinicians
regarding the safety and efﬁcacy of thrombolysis in acute
stroke. It has been stated, ‘‘The real scandal in acute stroke care
is not that thrombolytic therapy is being used, but that it is not
being used often or wisely enough.’’
24 A possible barrier to
physician adoption of stroke guidelines, following from the
pervasiveness of pharmaceutical funding, may be suggested to
have roots in physician distrust of the results.
25
In a speciﬁc example, based on the European Cooperative
Acute Stroke Study (ECASS III), the time window for treatment
of acute stroke is now expanded beyond the original 3 hours,
allowingtreatmentupto4.5hoursafterstrokeonset.
26Reviewof
the disclosures for the ECASS III publication indicates that the
study was sponsored by Boehringer Ingelheim, the manufacturer
of the study drug. Several authors of the study serve as paid
consultants to Boehringer Ingelheim, receive ﬁnancial honoraria
from Boehringer, or receive grant funding support from
Boehringer. Additionally, other authors of the study are directly
employed by Boehringer. Although none of these disclosures
proves a lack of integrity in the reporting of results, it is prudent
to interpret the reported outcomes with caution, given the
multifactorial risk of sponsorship bias.
A second barrier to the use of thrombolytic therapy
remains controversy within the specialty of emergency
medicine. The ACEP clinical policy regarding use of
thrombolytic therapy in acute stroke states that further data are
needed to deﬁne patients who will clearly beneﬁt from
thrombolytics, and that insufﬁcient evidence exists to support
thrombolytic use outside the conditions described in NINDS.
The AAEM policy statement speciﬁcally alludes to the
ﬁnancial interests at work in the guidelines. Additional authors
Table 2. Thrombolytic therapy agents.
Manufacturer Product
Abbott Laboratories prourokinase
AB Kabi Kabikinase (streptokinase)
Aventis Behringer Streptase (streptokinase)
Boehringer Ingelheim Actilyse (alteplase)
Bristol-Myers Squibb lanoteplase
Forest Laboratories desmoteplase
Genentech Activase (alteplase)
Hoechst Streptase (streptokinase)
Novo Nordisk Activase (alteplase)
PAION desmoteplase
Pharmacia Kabikinase (streptokinase)
Sanofi-Aventis Streptase (streptokinase)
Sumitomo Solclot (duteplase)
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contention that the NINDS study was too small, and that
baseline differences are found between the treatment and
placebo groups in both NINDS and ECASS III that account for
the entire apparent treatment effect.
27,28
Of further concern to physicians, despite the apparent
beneﬁt, may be the magnitude of the harm. Intracranial
hemorrhage is a grave and frequently fatal complication of
thrombolytic therapy, and many physicians may be hesitant to
associate themselves with this readily observable deterioration.
Emerging data appear to show that elderly patients are at
signiﬁcantly higher risk for deterioration with thrombolytic
therapy.
29 It may be prudent for proponents of thrombolytic
therapy to focus on narrowing the treatment group to patients
with more-favorable risk/beneﬁt proﬁles, rather than seeking to
expand the potential treatment group through time-window
extension.
Proponents of thrombolytic therapy may argue that it is
unethical to withhold an approved and ‘‘proven’’ treatment from
stroke victims to perform further trials. However, a favorable
outcome may have a positive effect on widespread adoption of
thrombolytic therapy. This resulting increase in the use of
thrombolytics may beneﬁt countless stroke victims who might
be denied therapy at present, far outnumbering the cohort of
patients who would be enrolled in an additional clinical trial. An
independent, randomized, controlled trial, such as the ongoing
International Stroke Trial-3,
30 may bring clarity.
Last, despite the ongoing controversy over efﬁcacy,
guideline-directed thrombolytic therapy is in use for acute
stroke. Its approval by the AHA as ‘‘deﬁnitely recommended’’
(Class I) therapy places individual physicians at risk for
litigation; physicians have been successfully sued both for use
of thrombolytic therapy in acute stroke and for its omission.
31
Professional organizations should take leadership roles in
protecting their constituents from litigation. This includes
encouraging further research to quell debate over efﬁcacy, as
well as issuing clear guidance on the standard of care that aids
physician defense during litigation.
CONCLUSION
Pharmaceutical ﬁnancial disclosures are prevalent in the
investigation of thrombolytic therapy for acute stroke.
Evidence from reviews of sponsorship bias suggests that it is
reasonable to question the outcomes as interpreted in these
studies. Individual physicians and professional associations
should encourage further independent, randomized, controlled
study of this intervention.
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